Consensus Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 11:35:01 2025-06-20 am EDT			5-day change	1st Jan Change
10.33 ^EUR	+2.33%		+1.32%	+12.92%

Jun. 20	European Equities Traded in the US as American Depositary Receipts Retreat Friday	MT
Jun. 19	Grifols Says Positive Fibrinogen Phase 3 Trial Results Published	RE

Evolution of the Average Target: Grifols, S.A.

Evolution of the Target Price: Grifols, S.A.

Changes in Analyst Recommendations: Grifols, S.A.

981bd1a13b20f713c8ab2a31c26dd.HMR9uQ0idWWhjz-EMpShfNiAw-taXCg73_Up2GFxNsk.VZcS7T9mMxbt9kj3V9_AG-HJtNwXEUBe54xRvAgmcf9O6RfaXFU3Kvbtag~c4be3df2074b1e2595a282fe701b3eb4

Analysts' recommendations: Grifols, S.A.

GRIFOLS : Governance and operational improvements are worthy of notice	May. 27
GRIFOLS : Invest Securities says undervalued	May. 20	CF
GRIFOLS : A healthy Q1 impressed investors	May. 13
GRIFOLS : Invest Securities raises its price target	Mar. 04	CF
GRIFOLS : Q4 24: Investors impressed with FCF generation and governance-related announcements	Feb. 27
GRIFOLS : No negative surprise in Q3 was good enough for the market	Nov. 08
GRIFOLS : All eyes on the upcoming takeover bid, despite some normalisation in our estimates	24-10-16
GRIFOLS : Operational improvements continued in the Q2; guidance maintained	24-07-31
GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion?	24-07-08
GRIFOLS : In line Q1 and on track deleveraging; worth a go	24-05-15
GRIFOLS : Factoring in a more moderate earnings recovery; long-term view intact	24-04-11
Invest Securities Keeps Grifols at Buy, Trims PT	24-03-01	MT
GRIFOLS : Market panic following yesterday’s conference call was unwarranted	24-03-01
GRIFOLS : Q4 in line; today’s adverse market reaction means a buying opportunity	24-02-29
GRIFOLS : Grifols accelerates its governance improvements post the short-seller’s allegations	24-02-07
GRIFOLS : Investors not impressed with the conference call; panic opens up attractive entry point	24-01-12
GRIFOLS : Dragged down by a short seller, but the management is ready to respond	24-01-10
GRIFOLS : Delivering on a much-needed deleveraging promise	24-01-02
GRIFOLS : Delivering on a much-needed deleveraging promise	24-01-02
JPMorgan Adjusts Grifols' Price Target to $10.50 From $10, Maintains Neutral Rating	23-12-05	MT
GRIFOLS : Persistently-high interest rate impacts our near-term estimates; fundamentals remain intact	23-11-07
Invest Securities Trims Grifols PT, Maintains Buy Rating	23-11-03	MT
GRIFOLS : Healthy Q3; deleveraging priorities remain on track	23-11-03
GRIFOLS : Good Q2; now all eyes on potential divestments	23-07-27
GRIFOLS : Spanish plasma giant making (gradual) progress	23-06-14

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
GRIFOLS, S.A.			+54.52%
CSL LIMITED			+30.87%
SAMSUNG BIOLOGICS CO.,LTD.			+29.81%
UCB			+33.45%
BIOGEN INC.			+35.35%
INNOVENT BIOLOGICS, INC.			-9.14%
ALTEOGEN INC.			+44.87%
INTRA-CELLULAR THERAPIES, INC.	-	-	-
INCYTE CORPORATION			+9.77%
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-	-	-14.41%
Average			+23.90%
Weighted average by Cap.			+27.07%